Quantum BioPharma Ltd. Clarifies Misinformation Regarding Name Change and RTO
Quantum BioPharma Ltd. (NASDAQ: QNTM) has officially denied rumors of a name change and reverse takeover involving Unbuzzd Wellness Inc., clarifying its financial and operational relationship with the company amidst preparations for Unbuzzd's potential IPO.
Quantum BioPharma Ltd. (NASDAQ: QNTM) has stepped forward to clarify widespread misinformation circulating on social media and stock trading platforms about a purported name change and reverse takeover (RTO) involving Unbuzzd Wellness Inc. The biopharmaceutical firm confirmed that it has not altered its name to unbuzzd and is not engaged in an RTO transaction, dispelling rumors that followed a recent press release dated May 29, 2025.
Despite being the largest shareholder and debt holder of Unbuzzd, Quantum BioPharma emphasized that the two companies operate independently. Quantum holds 200 million shares of Unbuzzd, a 7% royalty agreement on revenue up to $250 million, and a warrant that could increase its stake to 25%. Additionally, Quantum has provided Unbuzzd with a $1.3 million loan at a 10% interest rate over three years. Unbuzzd, under the leadership of former Coca-Cola executive John Duffy and ex-Celsius Holdings CEO Gerry David, is gearing up for a possible initial public offering (IPO), with MNP LLP conducting PCAOB audits in preparation.
In related news, Quantum BioPharma announced a forthcoming $20,930 debt settlement with two vendors, expected to be finalized in early June. This clarification comes at a critical time as both companies navigate the complexities of their financial and operational relationships, with significant implications for investors and the biopharmaceutical industry at large.